详情请浏览新闻稿．

详情请浏览新闻稿．

详情请浏览新闻稿．

董事会主席兼首席执行官Richard A. Gonzalez和执行领导团队成员将出席艾伯维的免疫业务和管道。

与会者密码:vYPrXP6 * * 56

前瞻性陈述
此沟通中的一些陈述可能是1995年私营证券诉讼改革法案的前瞻性陈述。“相信”，“预期”，“预期”，“项目”和类似表达，等等，普遍认为- 划分的陈述。ABBVIE注意到这些前瞻性陈述受风险和不确定性可能导致实际结果与前瞻性陈述中所示的实际结果不同。这种风险和不确定性包括但不限于交易所发生的可能性，交易的预期利益，对知识产权的挑战，来自其他产品的竞争，研究和开发过程中固有的困难，不利的诉讼或政府狗万正网地址行动，以及适用于我们行业的法律法规的变化。Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” in AbbVie’s 2014 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

附加信息和在哪里找到它

此沟通中引用的投标要约尚未开始。本公告仅供参考，既不是购买的要约，也不是招揽卖出股票的要约，也不是ABBVIE Inc.（“ABBVIE”）及其收购子公司将申请的招标提供材料的替代品the U.S. Securities and Exchange Commission (“SEC”). At the time the tender offer is commenced, AbbVie and its acquisition subsidiary will file a tender offer statement on Schedule TO, AbbVie will file a registration statement on Form S-4, and Pharmacyclics will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO EXCHANGE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION. PHARMACYCLICS STOCKHOLDERS ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF PHARMACYCLICS SECURITIES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING EXCHANGING THEIR SECURITIES. The Offer to Exchange, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of Pharmacyclics’ stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SEC’s website atwww.sec.gov．通过联系ABBVIE或PHARMACACLICS可以免费获得额外的副本。

除了Exchange要约、相关的递交函和某些其他招标要约文件，以及征集/推荐声明外，艾伯维还每年提交您可以阅读和复制艾伯维在美国证券交易委员会公共资料室提交的任何报告或其他信息。该资料室位于华盛顿特区20549,n.e. 100 F Street。请致电美国证券交易委员会1-800-SEC-0330查询有关公共资料室的进一步信息。公众还可以从商业文件检索服务和美国证交会维护的网站上查阅艾伯维向美国证交会提交的文件http://www.sec.gov．